JD-002

N/A

Report date: 2023/03/25 22:04:24

Base Information

Drug NameJD-002
Drug Alias NameJD-002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHunan Jynda Bioengineering Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHunan Jynda Bioengineering Co LtdXuzhou Medical University (Xzmu)
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A